Skip to content
Evigrade
ModerateVitamin K antagonist anticoagulants×Selective serotonin reuptake inhibitors (SSRIs)

Updated · Methodology

Mechanism

Acenocoumarol is a coumarin derivative and vitamin K antagonist: it reduces the activation of the vitamin K-dependent clotting factors II, VII, IX and X. Its effect is measured by the prothrombin time and the international normalised ratio (INR) (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish acenocoumarol SmPCs list sertraline among the selective serotonin reuptake inhibitors (SSRIs) that can potentiate its anticoagulant effect (AEMPS). SSRIs, sertraline included, raise the risk of bleeding on their own, and anticoagulants may add to this risk (sertraline SmPC, AEMPS; sertraline prescribing information, US Food and Drug Administration, FDA). The sertraline labels describe a combination study only with warfarin. Sertraline 200 mg a day caused a small but statistically significant prolongation of the prothrombin time, which in rare cases can change the INR (sertraline SmPC, AEMPS). CYP2C9 is the main enzyme in acenocoumarol metabolism, and according to its Spanish SmPC sertraline does not inhibit CYP2C9, CYP2C19 or CYP1A2 to a clinically significant degree (acenocoumarol and sertraline SmPCs, AEMPS).

Symptoms

The main risk is bleeding. Abnormal bleeding has been reported with selective serotonin reuptake inhibitors (SSRIs), sertraline included: bleeding into the skin (ecchymosis and purpura), gastrointestinal and gynaecological bleeding, including fatal bleeding (sertraline summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the US label, such bleeding ranges from ecchymoses, haematomas, nosebleeds and petechiae to life-threatening haemorrhage (sertraline prescribing information, US Food and Drug Administration, FDA). Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older and with concomitant treatment (acenocoumarol SmPC, AEMPS). With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints. Fast heartbeat, low blood pressure, nausea, vomiting, diarrhoea and abdominal pain may follow (AEMPS).

Management

The combination is not contraindicated but needs frequent coagulation monitoring. The acenocoumarol summaries of product characteristics (SmPC) ask for close and frequent coagulation checks, for example twice a week. This applies both when sertraline is added and when it is stopped (acenocoumarol SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish sertraline SmPC asks for caution when sertraline is combined with anticoagulants and in patients with a history of bleeding disorders. The US label says to inform patients of the increased risk of bleeding (sertraline SmPC, AEMPS; sertraline prescribing information, US Food and Drug Administration, FDA). Acenocoumarol is 98.7% bound to plasma proteins. With such highly bound drugs, monitor for adverse reactions and reduce the dose of sertraline or of the other drug as warranted (sertraline prescribing information, FDA; acenocoumarol SmPC, AEMPS). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose, spread as evenly as possible over seven days (acenocoumarol SmPC, AEMPS). With an international normalised ratio (INR) below 4.5 and minor bleeding, such as a short nosebleed or small isolated bruises, temporarily reducing or skipping a dose is often enough. With an INR of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, interrupt it and give 1–5 mg of vitamin K1 by mouth (AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute. In severe bleeding, replace clotting factors with fresh whole blood, prothrombin complex concentrate or recombinant factor VIIa together with vitamin K1 (AEMPS). After bleeding, restart acenocoumarol once the INR is back in the target range (AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Acenocoumarol

Other interactions with Sertraline